Each of the statistical testing strategies were based on the following principles: For a specific dose of semaglutide tablets (e.g., SEM 14 mg), demonstration of superiority on A1C was required before testing for superiority based on other outcomes, such as body weight Establishment of superiority for A1C was required at all higher dosages before continuing testing at lower dosages Non-inferiority must be demonstrated for comparisons to active treatments (or placebo in the CVOT) before testing for superiority PIONEER 9 did not report the use of a testing strategy to control for type 1 error and PIONEER 10 did not adjust for multiplicity
GIP receptor activation is studied for its effects on adipose tissue metabolism and insulin secretion enhancement, while GLP-1 receptor activation is examined for its appetite suppression, gastric emptying delay, and pancreatic beta-cell protection
This is body recomposition, and it is the ideal outcome
While this drives fat loss, the body also catabolizes muscle for energy when deficits become too large
Semaglutide can make those changes feel more manageable by helping reduce hunger and improve fullness, but daily habits still shape the outcome